Interview: Abramo Brandi – Managing Director, Octapharma Italy
Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis.…
SIFI is the leading Italian ophthalmic company, focused on eye care since its foundation in 1935.
SIFI designs, manufactures and markets innovative pharmaceutical products, surgical and medical devices.
SIFI’s mission is to provide ophthalmologists and their patients with a wide range of therapeutic solutions to treat the most common eye diseases.
Cutting-edge innovation, continuous development, a clear understanding of patients and caregivers needs, have shaped an extensive spectrum of eye care products, developed and marketed by SIFI main Italian and foreign branches.
Headquartered in Catania (Sicily), SIFI operates directly in Italy, Romania and Mexico with a staff of more than 330 people worldwide.
Since June 2015 SIFI is backed by 21 Investimenti, private equity firm founded by Alessandro Benetton, to support the company’s international expansion and portfolio development strategy.
For more information, please visit SIFI website www.sifigroup.com.
Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis.…
Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian…
Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the…
GE Healthcare Italy’s Marco Campione discusses patient access to innovation, synergies between pharma and medtech in companion diagnostics, and partnering with the Italian healthcare system. You have been working at…
Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the…
Simona Falciai, General Manager of Shionogi, provides insights into the launch of the Italian affiliate, how the company is catering to a key unmet medical need with Ospemifene, the first…
Outspoken Italian Managing Director of Israeli-based Teva, Hubert Puech d’Alissac, talks about his passion for social responsibility, adapting to the new realities of patient care in the digital age, and…
Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not…
The president of Chiesi explains how innovation and a strong focus on quality have led to outstanding growth and have established the Italian family-run business as a significant pharma player…
Dr. Osvaldo Ponchiroli, CEO of OP Pharma, discusses the expertise his company can offer to help navigate Italy’s regulatory environment, the outlook for medium-sized generics companies in Italy and OP’s…
Family-owned Laboratori Baldacci is something of a rare breed in an industry dominated by multinational players. The senior research manager discusses the history of the company as well as how…
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Now part of the Sanofi group, as SanofiGenzyme, it benefits from the reach and resources of…
See our Cookie Privacy Policy Here
